ENGN — enGene Holdings Income Statement
0.000.00%
Last trade - 00:00- $194.73m
- $4.31m
Annual income statement for enGene Holdings, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.3 | 14.1 | 19.4 | 29.2 | 62.7 |
| Operating Profit | -12.3 | -14.1 | -19.4 | -29.2 | -62.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.1 | -23.4 | -24.4 | -99.9 | -55.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.1 | -23.4 | -24.5 | -99.9 | -55.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.1 | -23.4 | -24.5 | -99.9 | -55.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.6 | -22.3 | -29 | -105 | -55.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.785 | -1.03 | -1.25 | -4.43 | -1.45 |